Chronic lymphocytic leukaemia


Nature Reviews Disease Primers 3, 16096 (2017)

In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.